Waverley Pharma Inc (WAVE) - Net Assets
Based on the latest financial reports, Waverley Pharma Inc (WAVE) has net assets worth CA$-2.73 Million CAD (≈ $-1.97 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$1.19 Million ≈ $864.14K USD) and total liabilities (CA$3.92 Million ≈ $2.84 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. For live market cap and overall valuation, see Waverley Pharma Inc (WAVE) total market value.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$-2.73 Million |
| % of Total Assets | -228.13% |
| Annual Growth Rate | N/A |
| 5-Year Change | -243.68% |
| 10-Year Change | N/A |
| Growth Volatility | 66.93 |
Waverley Pharma Inc - Net Assets Trend (2015–2025)
This chart illustrates how Waverley Pharma Inc's net assets have evolved over time, based on quarterly financial data.
Annual Net Assets for Waverley Pharma Inc (2015–2025)
The table below shows the annual net assets of Waverley Pharma Inc from 2015 to 2025. See Waverley Pharma Inc net asset quality index to measure how much of total assets are equity-financed.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CA$-2.57 Million ≈ $-1.86 Million |
-26.54% |
| 2024-12-31 | CA$-2.03 Million ≈ $-1.47 Million |
-78.72% |
| 2023-12-31 | CA$-1.14 Million ≈ $-822.30K |
-204.18% |
| 2022-12-31 | CA$1.09 Million ≈ $789.27K |
-39.02% |
| 2021-12-31 | CA$1.79 Million ≈ $1.29 Million |
-12.42% |
| 2020-12-31 | CA$2.04 Million ≈ $1.48 Million |
-28.20% |
| 2019-12-31 | CA$2.85 Million ≈ $2.06 Million |
-28.37% |
| 2018-12-31 | CA$3.97 Million ≈ $2.87 Million |
-21.44% |
| 2017-12-31 | CA$5.06 Million ≈ $3.66 Million |
+43602.49% |
| 2016-12-31 | CA$-11.62K ≈ $-8.41K |
-10.22% |
| 2015-12-31 | CA$-10.55K ≈ $-7.63K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Waverley Pharma Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1083078900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CA$8.27 Million | % |
| Total Equity | CA$-2.57 Million | 100.00% |
Waverley Pharma Inc Competitors by Market Cap
The table below lists competitors of Waverley Pharma Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
African Dawn Capital Ltd
JSE:ADW
|
$586.01K |
|
ArcelorMittal SA
LSE:0RP9
|
$586.22K |
|
Nulegacy Gold Corporation
V:NUG
|
$586.40K |
|
Hitech & Development Wireless Sweden Holding AB (publ)
ST:HDW-B
|
$588.92K |
|
Discovery Harbour Resources Corp
V:DHR
|
$584.17K |
|
PT Century Textile Industry Tbk
JK:CNTX
|
$582.44K |
|
FINCANNA CAPITAL CORP.
F:4AL0
|
$582.22K |
|
CHINA HEALTH GRP HD-10
F:VNL1
|
$581.84K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Waverley Pharma Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -2,031,562 to -2,570,705, a change of -539,143.
- Net loss of 499,214 reduced equity.
- Other factors decreased equity by 39,929.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$-499.21K | -19.42% |
| Other Changes | CA$-39.93K | -1.55% |
| Total Change | CA$- | % |
Book Value vs Market Value Analysis
This analysis compares Waverley Pharma Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CA$0.09 | CA$0.02 | x |
| 2018-12-31 | CA$0.07 | CA$0.02 | x |
| 2019-12-31 | CA$0.05 | CA$0.02 | x |
| 2020-12-31 | CA$0.04 | CA$0.02 | x |
| 2021-12-31 | CA$0.03 | CA$0.02 | x |
| 2022-12-31 | CA$0.02 | CA$0.02 | x |
| 2023-12-31 | CA$-0.02 | CA$0.02 | x |
| 2024-12-31 | CA$-0.04 | CA$0.02 | x |
| 2025-12-31 | CA$-0.05 | CA$0.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Waverley Pharma Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -36.99%
- • Asset Turnover: 1.08x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-24.09%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-9.59K |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | CA$84.40 |
| 2017 | -46.63% | 0.00% | 0.00x | 1.32x | CA$-2.86 Million |
| 2018 | -35.77% | -635.95% | 0.04x | 1.32x | CA$-1.82 Million |
| 2019 | -42.69% | -104.97% | 0.26x | 1.54x | CA$-1.50 Million |
| 2020 | -34.55% | -51.32% | 0.39x | 1.71x | CA$-910.05K |
| 2021 | -44.52% | -45.44% | 0.48x | 2.06x | CA$-975.42K |
| 2022 | -60.86% | -53.26% | 0.46x | 2.46x | CA$-773.18K |
| 2023 | 0.00% | -539.70% | 0.43x | 0.00x | CA$-2.11 Million |
| 2024 | 0.00% | -199.23% | 0.23x | 0.00x | CA$-743.92K |
| 2025 | 0.00% | -36.99% | 1.08x | 0.00x | CA$-242.14K |
Industry Comparison
This section compares Waverley Pharma Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $16,096,450
- Average return on equity (ROE) among peers: -139.54%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Waverley Pharma Inc (WAVE) | CA$-2.73 Million | 0.00% | N/A | $585.94K |
| Appili Therapeutics Inc (APLI) | $-10.92 Million | 0.00% | 0.00x | $1.39 Million |
| Aptose Biosciences Inc (APS) | $93.93 Million | -27.98% | 0.07x | $4.43 Million |
| Arch Biopartners Inc (ARCH) | $-887.26K | 0.00% | 0.00x | $50.62 Million |
| Biomind Labs Inc (BMND) | $-247.66K | 0.00% | 0.00x | $38.72 Million |
| Cybin Inc (CYBN) | $86.12 Million | -37.41% | 0.07x | $301.37 Million |
| Eastwood Bio-Medical Canada Inc (EBM) | $-840.80K | 0.00% | 0.00x | $89.55 Million |
| Eupraxia Pharmaceuticals Inc (EPRX) | $-21.66 Million | 0.00% | 0.00x | $376.64 Million |
| Devonian Health Group Inc (GSD) | $10.08 Million | -29.57% | 0.70x | $21.55 Million |
| Helix BioPharma Corp. (HBP) | $4.92 Million | -31.91% | 0.19x | $107.19 Million |
| Hemostemix Inc (HEM) | $487.80K | -1268.49% | 2.41x | $10.23 Million |
About Waverley Pharma Inc
Waverley Pharma Inc., a biopharmaceutical company, researches, develops, and commercializes oncology therapeutics in the United Kingdom. The company develops PARP-1 Inhibitors for cancer treatment. It also operates a retail pharmacy in the United States. In addition, it is involved in the sale of prescription medications, over-the-counter products, and associated pharmacy services. Waverley Pharm… Read more